Angiopoietin-2 inhibitor

0 marketed 1 in Phase 2 1 in Phase 1

This page covers all Angiopoietin-2 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Angiopoietin-2.

Targets

Phase 2 pipeline (1)

AMG 386 with or without Trastuzumab · QuantumLeap Healthcare Collaborative · Oncology
AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing its interaction with its receptor, thereby inhibiting angiogenesis.

Phase 1 pipeline (1)

AMG 386, paclitaxel and carboplatin · Amgen · Oncology
Angiopoietin-2 inhibitor